GlassScriptPhysician profile
Roshen Mathew
NPI 1447563812
$19,027.81
in general payments reported to CMS, 2019-2025
23 companies · $4,306 in 2025
The $4,306 reported for 2025 was more than what 87% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,893 · 2020: $617 · 2021: $114 · 2022: $1,367 · 2023: $2,617 · 2024: $7,115 · 2025: $4,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,350 · Travel and Lodging: $3,280 · Education: $2,800 · Food and Beverage: $608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,350.00 |
| Travel and Lodging | $3,279.72 |
| Education | $2,800.00 |
| Food and Beverage | $608.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noah Medical Corporation | $13,850.05 | 2023-2025 | Galaxy |
| Pulmonx Corporation | $1,506.61 | 2019-2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Veran Medical Technologies, INC. | $1,333.55 | 2019-2020 | |
| Boston Scientific Corporation | $999.03 | 2019-2020 | |
| Pinnacle Biologics, INC | $200.00 | 2019 | |
| Glaxosmithkline, LLC. | $186.83 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $136.48 | 2019-2020 | |
| Philips North America LLC | $135.92 | 2019 | |
| Sunovion Pharmaceuticals INC. | $113.96 | 2019 | |
| Ethicon INC. | $96.03 | 2025 | Monarch Platform |
| Genentech USA, INC. | $93.13 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.14 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.45 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $57.32 | 2019-2020 | |
| Mylan Specialty L.P. | $34.56 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $31.51 | 2019 | |
| Shire North American Group INC | $20.20 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.79 | 2019 | |
| Intuitive Surgical, INC. | $15.33 | 2022 | |
| Insmed, INC. | $14.57 | 2020 | |
| Phadia US INC. | $12.16 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.10 | 2020 | |
| Electromed, INC. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roshen Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.